Research
Hormonal
GLP-1 RAs reduce Major Adverse Cardiovascular Events (MACE) by 14-20% in patients with Type 2 Diabetes and Obesity, independent of glycemic control.
GLP-1 medications significantly reduce the risk of heart attacks, strokes, and cardiovascular death in people with diabetes or obesity. This benefit exists even if blood sugar control is not the primary goal. Discuss cardiovascular risk with your doctor to see if a GLP-1 RA is appropriate.
StrongSupportsHIGH confidence
Established applications demonstrate robust efficacy in... cardiovascular protection (14–20% reduction in major adverse cardiovascular events, or MACE).
Why this rating
Based on large-scale cardiovascular outcome trials (SELECT, LEADER, SUSTAIN-6, etc.).
Source
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Shikha Patel et al. · Pharmaceutics · 2025
Meta-analysisCited 14×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →